News
SeaLife’s shareholders decide on capital increase of T€ 800
To support the companies activities in pharmaceutical development and engagement in the registration of a new active substance in Biocidal/MedTech market, SeaLife’s shareholders to increase capital from shareholder funds in July 2015.
SeaLife secures funding for development of new active substance in Biocide/MedTech field
SeaLife secures fresh funding from a basic grant of The Austrian Research Promotion Agency (FFG) in May 2015. The fund supports the development of SeaLife’s polymeric agent SLP0901 to enter the market as new active substance in the Biocide/MedTech field.
SeaLife gets second EU funding for marine drug discovery
SeaLife Pharma GmbH is proud to announce that it has partnered in the EU FP7 funded project named Macumba - Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications, with a total funding of 12 Mio € and 23 partners from 11 nations.
Antibiotics from under the sea
38-year old marine biologist Alexander Pretsch has made it his startup’s mission to find a drug against problematic bacteria, such as MRSA, Streptococcus or Enterococci – a mission whose goal is becoming more and more attainable ...
SeaLife Pharma becomes partner in EU funded PharmaSea Project
Sealife is pleased to announce that it has become a partner in the PharmaSea project funded by the European Union under its FP7 program. This project focuses on bio-discovery research, development and commercialization of new substances from marine organisms. Its primary goal is to collect marine samples ...
Gefährliche Keime in Spitälern – Forscher in Tulln entwickeln wirksamere Antibiotika
Sie sind der Schrecken aller Mediziner: Krankheitskeime, die gengen herkömmliche Antibiotika "immun" sind. Forscher in Tulln haben jetzt Präparate entwickelt, die es sogar mit diesen aggressiven Erregern aufnehmen ...
First success with new antibiotic class from under the sea
Biotech startup SeaLife registered first promising results with their drug against multi-resistant bacteria. Components discovered in the sea, the novel antibiotic class (SLP0905) was tested in laboratory and proved effective against dangerous pathogens such as MRSA, Streptococcus or Enterococci...
The Pharmacy from the ozean
Antibiotics. SeaLife Pharma searches for active agents against multi drug resistent bacteria under water ...
New study confirms Antimicrobial and Anti-Inflammatory Activities of Endophytic Fungi Talaromyces wortmannii Extracts against Acne-Inducing Bacteria
Acne vulgaris is the most common skin disease, causing significant psychosocial problems such as anxiety and depression similar to a chronic illness for those afflicted. Currently, obtainable agents for acne treatment have limited use. Thus, development of novel agents to treat this disease is a high medical need ...
SeaLife gets new funding for its antibiotic lead development
Based on the successful development in the first two years of SeaLife antibiotic lead program, the company gets follow up funding from The Austrian Research Promotion Agency (FFG)...
SeaLife CEO holds chair in Annual World Congress of Marine Biotechnology
BIT's 2nd Annual Congress of Marine Biotechnology successfully held in Dalian World Expo Center with participants from more than 25 countries ...
